Epistem Regulatory News (EHP)

Epistem Holdings Plc ("Epistem" or the "Company")

Directors' shareholdings and issue of equity

Epistem (AIM: EHP), the biotechnology and personalised medicine company, today announces the following transactions by two of its Directors and the application for 117,000 new ordinary shares of £0.015 each to be admitted to trading on AIM.

On 19 December 2011, Jeffrey Moore, Managing Director Novel Therapies, exercised options over 29,000 ordinary shares at an exercise price of 120p per share.  On the same day, Jeffrey Moore disposed of 29,000 ordinary shares at a price of 350p per share.  Following these transactions, Jeffrey Moore has a beneficial interest in 15,348 ordinary shares (0.17%) and also has options granted but not yet exercised over a total of 320,999 ordinary shares. 

On 19 December 2011, Robert Nolan, a non-executive Director, sold 3,000 ordinary shares at a price of 350p per share.  Following this disposal Robert Nolan has a beneficial interest in 5,065 ordinary shares (0.06%) and also has options granted but not yet exercised over a total of 93,528 ordinary shares.

Application has been made for 117,000 new ordinary shares of £0.015 each to be admitted to trading on AIM.  The application has been made in respect of options exercised under the terms of the 2007 Epistem EMI scheme.  Admission in respect of 117,000 new ordinary shares is expected to be effective on 23 December 2011 and, when issued, the 117,000 new ordinary shares will rank pari passu in all respects with the Company's existing ordinary shares.  Following admission of the 117,000 new ordinary shares, Epistem will have 8,844,381 ordinary shares of £0.015 in issue.

For further details please contact:

Epistem Plc

Matthew Walls: Chief Executive Officer +44 (0) 161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel +44 (0) 20 7418 8900

Vijay Barathan